C4 Therapeutics, Inc. CCCC
Set alert
3.24 USD +0.02 +0.78%
As of Nov 3, 12:37 PM ET
3.23 Day range 3.42
1.69 52-week range 5.17
- YTD
- +69.37%
- 1 year
- +30.44%
- Open
- 3.25
- Prev close
- 3.21
- Mkt cap
- 397.37M
- Vol
- 926.05K
- Avg vol
- 2.44M
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.23
- High
- 3.42
- Forward P/E
- -2.37
- Beta
- 3.06
- Short ratio
- 7.10
- Inst. own
- 91.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 1, 2024
- 50-d avg
- 5.06
- 200-d avg
- 5.96
- 1y target
- 15.00
6M chart
Signals (19)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| SMA: Bullish | Oct 30, 2026 | 4 days ago |
| SMA: Bearish | Oct 29, 2026 | 5 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 6, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| RSI: Overbought | May 29, 2026 | 5 months ago |
| RSI: Overbought | May 13, 2026 | 5 months ago |
| MACD: Buy Signal | May 7, 2026 | 6 months ago |
Financial health
Altman Z-Score
-1.07 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 3
Valuation
P/E -1.5×
FY 2018 5y median -2.3× FY 2025
P/S 4.4×
FY 2018 5y median 9.3× FY 2025
P/B 0.6×
FY 2018 5y median 1.1× FY 2025
P/FCF -1.6×
FY 2018 5y median -2.6× FY 2025
EV/EBITDA -1.4×
FY 2018 5y median -2.5× FY 2025
EV/Sales 4.0×
FY 2018 5y median 10.8× FY 2025
FCF Yield -62.7%
FY 2018 5y median -38.7% FY 2025
Profitability
Gross Margin 77.8%
FY 2018 5y median 100.0% FY 2025
Operating Margin -290.7%
FY 2018 5y median -336.1% FY 2025
Net Margin -292.1%
FY 2018 5y median -296.0% FY 2025
ROE -40.9%
FY 2018 5y median -44.3% FY 2025
ROIC -31.4%
FY 2018 5y median -32.9% FY 2025
ROA -29.2%
FY 2018 5y median -29.8% FY 2025
Growth (YoY)
Revenue 1.0%
FY 2018 FY 2025
Operating Income 12.6%
FY 2018 FY 2025
EPS (diluted) 16.4%
FY 2018 FY 2025
Free Cash Flow -52.0%
FY 2018 FY 2025
Financial Health
Current Ratio 7.8×
FY 2018 5y median 6.4× FY 2025
Quick Ratio 7.8×
FY 2018 5y median 6.4× FY 2025
Debt / Equity 0.2×
FY 2018 5y median 0.3× FY 2025
Net Debt / EBITDA 0.1×
FY 2018 5y median 0.1× FY 2025
Interest Coverage 0.0×
FY 2018 5y median -38.3× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
